Epioxa, the first FDA-approved epithelium-on cross-linking procedure, is now commercially available, according to a press ...

Keratoconus is a rare, progressive ophthalmic disorder characterized by changes to the cornea that result in significant ...

Please provide your email address to receive an email when new articles are posted on . Cross-linking is a resource-intensive procedure. Designating cross-linking “champions” will help improve and ...

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for ...

Commercial rollout includes direct purchasing and specialty distribution, alongside scaled investments in awareness, ...

Credit: Glaukos. Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for ...

Patients in Somerset with keratoconus, an eye condition that causes blurred vision and sensitivity to light, can now access ...